118 related articles for article (PubMed ID: 6979651)
1. 2'-Deoxycoformycin-induced hemolysis in the mouse.
Spremulli E; Crabtree GW; Dexter DL; Diamond I; Calabresi P
J Natl Cancer Inst; 1982 Jun; 68(6):1011-4. PubMed ID: 6979651
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
[TBL] [Abstract][Full Text] [Related]
3. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
4. Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin).
Spremulli EN; Crabtree GW; Dexter DL; Chu SH; Farineau DM; Ghoda LY; McGowan DL; Diamond I; Parks RE; Calabresi P
Cancer Treat Rep; 1983 Mar; 67(3):267-74. PubMed ID: 6600968
[TBL] [Abstract][Full Text] [Related]
5. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
[TBL] [Abstract][Full Text] [Related]
7. Deoxycoformycin: neurological toxicity.
Major PP; Agarwal RP; Kufe DW
Cancer Chemother Pharmacol; 1981; 5(3):193-6. PubMed ID: 6975188
[TBL] [Abstract][Full Text] [Related]
8. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of deoxycoformycin: effect of constant infusion on adenosine deaminase, adenosine, 2'-deoxyadenosine and monoamines in the mouse brain.
Helland S; Broch OJ; Ueland PM
Neuropharmacology; 1983 Jul; 22(7):915-7. PubMed ID: 6604884
[TBL] [Abstract][Full Text] [Related]
10. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
Earle MF; Glazer RI
Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
[No Abstract] [Full Text] [Related]
11. Association of severe and fatal infections and treatment with pentostatin.
O'Dwyer PJ; Spiers AS; Marsoni S
Cancer Treat Rep; 1986 Sep; 70(9):1117-20. PubMed ID: 3488805
[TBL] [Abstract][Full Text] [Related]
12. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
Smith CM; Belch A; Henderson JF
Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
[No Abstract] [Full Text] [Related]
13. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
Brox L; Ng A; Pollock E; Belch A
Cancer Res; 1984 Mar; 44(3):934-7. PubMed ID: 6607110
[TBL] [Abstract][Full Text] [Related]
14. Effects of deoxycoformycin in mice. I. Suppression and enhancement of in vivo antibody responses to thymus-dependent and -independent antigens.
Ratech H; Bell MK; Hirschhorn R; Thorbecke GJ
J Immunol; 1984 Jun; 132(6):3071-6. PubMed ID: 6609968
[TBL] [Abstract][Full Text] [Related]
15. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
Koller CA; Mitchell BS
Cancer Res; 1983 Mar; 43(3):1409-14. PubMed ID: 6600652
[TBL] [Abstract][Full Text] [Related]
16. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
17. 2'-deoxycoformycin. A new anticancer agent.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
Blatt J; Venner PM; Riccardi R; Cohen LF; Gangji D; Glazer RI; Poplack DG
J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
[TBL] [Abstract][Full Text] [Related]
19. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
Matsumoto SS; Yu AL; Yu J
Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
Cass CE; Selner M; Tan TH; Muhs WH; Robins MJ
Cancer Treat Rep; 1982 Feb; 66(2):317-26. PubMed ID: 6976834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
